Immunome (IMNM) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Immunome (IMNM) over the past year, gaining 99.9% versus a gain of 36.8%. Over five years, TVTX leads with a +112.8% price change compared with +11.0% for IMNM. Travere Therapeutics is the larger company by market cap ($4.91 billion vs $2.31 billion), about 2.1 times the size.
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | TVTX |
|---|---|---|
| Share price | $19.55 | $52.13 |
| Market cap | $2.31B | $4.91B |
| 1-day change | +1.24% | +0.16% |
| YTD return | -8.99% | +36.42% |
| 1-year return | +36.81% | +99.94% |
| 5-year return | +11.02% | +112.76% |
| Forward P/E | — | 9.24 |
| EPS (TTM) | $-2.55 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $490.73M |
| Revenue growth (YoY) | -23.23% | +110.45% |
| Net income (latest FY) | $-212.39M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | -3228.83% | -12.80% |
| Net margin | -3059.99% | -5.21% |
| 52-week high | $30.06 | $68.73 |
| 52-week low | $13.54 | $22.59 |
| Distance from 52-week high | -34.96% | -24.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +80.05% | +44.29% |
| Average volume | 1.21M | 1.59M |
| Shares outstanding | 118.00M | 94.26M |
| Employees | 247 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Travere Therapeutics is about 2.1 times larger than Immunome by market value ($4.91B vs $2.31B).
- TVTX has outperformed IMNM by 63.1 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
IMNM vs TVTX FAQ
Which is bigger, Immunome or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.91B compared with $2.31B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or TVTX?
TVTX returned +99.94% over the past 12 months, compared with +36.81% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.